What is ZVRA's market cap?

$663.32M, based on the Nov 4 close of $11.17.

What is ZVRA's P/E ratio?

8.6× trailing-twelve-month earnings of $76.87M.

Does Zevra Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ZVRA is sold short?

6.2M shares, 10.8% of float, as of Oct 15, 2026.

What sector is ZVRA in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ZVRAHealthcarePharmaceuticals

Zevra Therapeutics, Inc. Common Stock (ZVRA)

$11.17+8.87%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$10.88▲ 6.56% in range

Nov 3, 2025Low $8.10 · High $14.75Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Zevra Therapeutics closed at $11.17 on Nov 4, up 8.87%, 24.3% below its 52-week closing high. Volume of 2.1M shares was 2.95× its 20-day average (well above normal).

Split-adjusted performance: +4.1% over one month, -0.7% over six months, +9.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $37.76M, up 44.9% from a year earlier, with a net margin of 48.8%.

Short interest was 6.2M shares at the Oct 15 settlement, down 12.9% from the prior report (10.8% of float, 7.1 days to cover).

Market cap$663.3M59.4M shares

Revenue · quarter$37.8M+44.9% YoY

Diluted EPS$0.26—

P/E · TTM8.6×P/S 4.5×

Net margin48.8%Gross 95.2%

Dividend yieldNone

52-week range8.10 – 14.75−24.3% from high

Volume2.1M2.95× 20-day avg

Volatility · 60d47.6%Annualised

Short % of float10.8%7.1 days to cover

Net cash$188.3MCash $195.6M

Next earnings—Not scheduled

Split-adjusted performance

1W +8.3%1M +4.1%3M −6.0%6M −0.7%YTD +24.7%1Y +9.4%3Y +158.0%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum71

Revenue growth77

Net margin95

Value (low P/E)72

Size65

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short6.2M−12.9% vs prior

Days to cover7.1Settled Oct 15

% of float10.8%

Short vol. 10d63.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ZVRAZevra Therapeutics	$11.17	+8.87%	−0.7%	+44.9%	48.8%	8.6	$663.3M
AVBPArriVent BioPharma	$13.49	+3.61%	−54.5%	—	—	—	$665.2M	Compare
DSGNDesign Therapeutics	$10.63	+2.80%	−26.9%	—	—	—	$665.2M	Compare
IMMXImmix Biopharma	$7.97	+3.37%	−22.8%	—	—	—	$660.7M	Compare
OLMAOlema Pharmaceuticals	$7.54	+2.58%	−50.4%	—	—	—	$659.7M	Compare
LXRXLexicon Pharmaceuticals	$1.48	+1.37%	−7.5%	−97.6%	−4591.8%	—	$658.5M	Compare
KURAKura Oncology	$7.61	−22.98%	−20.4%	+36.5%	−327.3%	—	$677.0M	Compare
OBXObsidian Therapeutics	$10.99	−16.93%	—	—	—	—	$678.9M	Compare
APMDApnimed	$15.30	+1.59%	—	—	—	—	$637.0M	Compare

News about Zevra Therapeutics

All news →

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · 1d ago▲ Positive Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionGlobeNewswire Inc. · Jul 24, 2026▼ Negative

Quick answers

What does Zevra Therapeutics do?: Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs.
What is ZVRA's market cap?: $663.32M, based on the Nov 4 close of $11.17.
What is ZVRA's P/E ratio?: 8.6× trailing-twelve-month earnings of $76.87M.
Does Zevra Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ZVRA is sold short?: 6.2M shares, 10.8% of float, as of Oct 15, 2026.
What sector is ZVRA in?: Healthcare, in the Pharmaceuticals industry.

About Zevra Therapeutics

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

HQ: Boston, MA61 employeesListed Apr 16, 2015zevra.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology